Sodium aurothiomalate

Sodium aurothiomalate Basic information
Product Name:Sodium aurothiomalate
Synonyms:chrysothios;disodiumaurothiomalate;kidon;mercapto-butanedioicacimonogold(1+)sodiumsalt;mercapto-succinicacigoldsodiumsalt;miochrysin;myochrysine;myocrisin
CAS:12244-57-4
MF:C4H7AuNaO4S
MW:371.11
EINECS:235-479-7
Product Categories:Organic-metal salt
Mol File:12244-57-4.mol
Sodium aurothiomalate Structure
Sodium aurothiomalate Chemical Properties
storage temp. 4°C, away from moisture
Water Solubility Very soluble in water. Practically insoluble in alcohol, ether
Merck 14,4518
Safety Information
Hazard Codes Xn
Risk Statements 20/21/22-43
Safety Statements 36
WGK Germany 3
RTECS MD5435000
Hazardous Substances Data12244-57-4(Hazardous Substances Data)
MSDS Information
ProviderLanguage
ALFA English
Sodium aurothiomalate Usage And Synthesis
Physical propertiesWhite to yellowish white powder; odorless; metallic taste; highly soluble in water; practically insoluble in ethanol and ether.
UsesMedicine (antirheumatic).
UsesSodium aurothiomalate(I) is useful for high mobility group box chromosomal protein 1 western blotting.
DefinitionWhite to yellowish-white powder; odorless; metallic taste. Affected by light. Very soluble in water; practically insoluble in alcohol and ether; aqueous solutions are colorless to pale yellow; pH (5% solution) 5.8–6.5.
Production MethodsGold(I) thiomalate is prepared by reacting sodium thiomalate with gold(I) halide. It is stored in the dark and otherwise protected from light.
Brand nameMyochrysine (Merck).
Pharmaceutical ApplicationsSodium aurothiomalate is a commonly used gold-based DMARD and is indicated for active progressive RA. It is administered by deep intramuscular injection. Administration is started with a test dose of 10mg followed by weekly intervals of 50 mg doses. An improvement is expected to be seen once 300–500 mg is administered. Treatment should be discontinued if there is no improvement after administering 1 g or 2months. Intervals of administration should be gradually increased to 4weeks in patients in whom an effect can be seen. If any blood disorders or other side effects such as GI bleedings or proteinuria are observed, sodium aurothiomalate should be discontinued.
Clinical UseActive progressive rheumatoid arthritis in adults
Safety ProfilePoison by subcutaneous and intramuscular routes. Moderately toxic bj intravenous ' route. Human systemic effects: aggression, agranulocytosis, aplastic anemia, cell count changes, changes in circulation, cholestatic jaunhce, dermatitis, encephalitis, fasciculations, flaccid paralysis without anesthesia, hemorrhage, hepatitis (hepatocellular necrosis), increased body temperature, interstitial fibrosis, muscle weakness, proteinuria, recording from peripheral motor nerve, depressed renal function tests, somnolence, structural changes in nerve sheath, thrombocytopenia, uncharacterized allergc reaction, changes in blood, teeth, and supporting structures. Experimental teratogenic and reproductive effects. When heated to decomposition it emits very toxic Na2O and SOx.
Drug interactionsPotentially hazardous interactions with other drugs
ACE-inhibitors: flushing and hypotension reported in combination.
Penicillamine: increased risk of toxicity - avoid.

MetabolismMainly excreted in the urine with smaller amounts in the faeces.
Sodium aurothiomalate Preparation Products And Raw materials
PENTOSAN POLYSULFATE SODIUM Sodium tetrachloroaurate Sodium benzoate Sodium thioglycolate sodium 2-Mercaptobutyric acid Mercaptosuccinic acid Diclofenac sodium Sodium silicate SODIUM AUROTHIOMALATE HYDRATE Sodium Monofluorophosphate Disodium succinate Sodium formate Sodium citrate Sodium chlorate Sodium bicarbonate Sodium chlorite Sodium aurothiomalate

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.